- Home
- FMST vs RDHL Comparison
FMST vs RDHL Comparison
Compare FMST & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- RDHL
- Stock Information
- Founded
- FMST 2005
- RDHL 2009
- Country
- FMST Canada
- RDHL Israel
- Employees
- FMST N/A
- RDHL N/A
- Industry
- FMST Other Metals and Minerals
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- RDHL Health Care
- Exchange
- FMST Nasdaq
- RDHL Nasdaq
- Market Cap
- FMST 15.8M
- RDHL 8.6M
- IPO Year
- FMST N/A
- RDHL N/A
- Fundamental
- Price
- FMST $1.60
- RDHL $6.50
- Analyst Decision
- FMST
- RDHL
- Analyst Count
- FMST 0
- RDHL 0
- Target Price
- FMST N/A
- RDHL N/A
- AVG Volume (30 Days)
- FMST 34.3K
- RDHL 21.3K
- Earning Date
- FMST 01-01-0001
- RDHL 12-27-2024
- Dividend Yield
- FMST N/A
- RDHL N/A
- EPS Growth
- FMST N/A
- RDHL N/A
- EPS
- FMST N/A
- RDHL N/A
- Revenue
- FMST N/A
- RDHL $3,707,000.00
- Revenue This Year
- FMST N/A
- RDHL $224.90
- Revenue Next Year
- FMST N/A
- RDHL $82.69
- P/E Ratio
- FMST N/A
- RDHL N/A
- Revenue Growth
- FMST N/A
- RDHL N/A
- 52 Week Low
- FMST $1.32
- RDHL $6.00
- 52 Week High
- FMST $3.50
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- FMST 46.69
- RDHL 38.21
- Support Level
- FMST $1.43
- RDHL $6.00
- Resistance Level
- FMST $1.77
- RDHL $7.30
- Average True Range (ATR)
- FMST 0.20
- RDHL 0.51
- MACD
- FMST 0.05
- RDHL -0.09
- Stochastic Oscillator
- FMST 61.76
- RDHL 21.10
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.